PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Phloroglucinol→

Phloroglucinol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
108-73-6
Molecular formula
C6H6O3
Molecular weight
126.11 g/mol
Drug class
Non-anticholinergic smooth-muscle antispasmodic
Mechanism of action
Relaxes smooth muscle and reduces spasm. A proposed mechanism includes inhibition of catechol-O-methyltransferase (COMT)-related signalling and modulation of calcium-dependent contractile activity; the clinical mechanism is not completely established.
Indications / reported uses
  • Symptomatic relief of painful smooth-muscle spasm of the gastrointestinal, biliary and urinary tracts where phloroglucinol-containing products are authorised.

Sources: https://www.ema.europa.eu/en/documents/mrl-report/phloroglucinol-trimethylphloroglucinol-summary-report-committee-veterinary-medicinal-products_en.pdf · https://pubmed.ncbi.nlm.nih.gov/?term=phloroglucinol+antispasmodic+clinical · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Phloroglucinol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phloroglucinol Permitted Daily Exposure (PDE) report (the Phloroglucinol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phloroglucinol Occupational Exposure Limit (OEL) report (the Phloroglucinol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.